Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis
Chee Khoon Lee,Michael L. Friedlander,Angelina Tjokrowidjaja,Jonathan A. Ledermann,Robert L. Coleman,Mansoor R. Mirza,Ursula A. Matulonis,Eric Pujade‐Lauraine,Ralph Bloomfield,Sandra Goble,Ping Wang,Rosalind M. Glasspool,Clare L. Scott,the Gynecologic Cancer Intergroup Meta‐Analysis Committee,
DOI: https://doi.org/10.1002/cncr.33517
IF: 6.9209
2021-03-19
Cancer
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> BACKGROUND</h3><p>The authors performed a meta‐analysis to better quantify the benefit of maintenance poly(ADP‐ribose) polymerase inhibitor (PARPi) therapy to inform practice in platinum‐sensitive, recurrent, high‐grade ovarian cancer for patient subsets with the following characteristics: germline <i>BRCA</i> mutation (<i>gBRCAm</i>), somatic <i>BRCA</i> mutation (<i>sBRCAm</i>), wild‐type <i>BRCA</i> but homologous recombinant‐deficient (HRD), homologous recombinant‐proficient (HRP), and baseline clinical prognostic characteristics. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> METHODS</h3><p>Randomized trials comparing a PARPi versus placebo as maintenance treatment were identified from electronic databases. Treatment estimates of progression‐free survival were pooled across trials using the inverse variance weighted method.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> RESULTS</h3><p>Four trials included 972 patients who received a PARPi (olaparib, 31%; niraparib, 35%; or rucaparib, 34%) and 530 patients who received placebo. For patients who had germline <i>BRCA1</i> mutation (<i>gBRCAm1</i>) (N = 471), the hazard ratio (HR) was 0.29 (95% CI, 0.23‐0.37); for those who had germline <i>BRCA2</i> mutation (<i>gBRCAm2</i>) (N = 236), the HR was 0.26 (95% CI, 0.17‐0.39); and, for those who had <i>sBRCAm</i> (N = 123), the HR was 0.22 (95% CI, 0.12‐0.41). The treatment effect was similar between the <i>gBRCAm</i> and s<i>BRCAm</i> subsets (<i>P</i> = .48). In patients who had wild‐type <i>BRCA</i> HRD tumors (excluding <i>sBRCAm</i>; N = 309), the HR was 0.41 (95% CI, 0.31‐0.56); and, in those who had wild‐type <i>BRCA</i> HRP tumors (N = 346), the HR was 0.64 (95% CI, 0.49‐0.83). The relative treatment effect was greater for the <i>BRCAm</i> versus HRD (<i>P</i> = .03), <i>BRCAm</i> versus HRP (<i>P</i> < .00001), and HRD versus HRP (<i>P</i> < .00001) subsets. There was no difference in benefit based on age, response after recent chemotherapy, and prior bevacizumab. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> CONCLUSIONS</h3><p>In platinum‐sensitive, recurrent, high‐grade ovarian cancer, maintenance PARPi improves progression‐free survival for all patient subsets. PARPi therapy has a similar magnitude of benefit for <i>sBRCAm</i> and <i>gBRCAm</i>. Although patients with <i>BRCAm</i> derive the greatest benefit, the absence of a <i>BRCAm</i> or HRD could not be used to exclude patients from maintenance PARPi therapy. </p></section>
oncology